PMID- 33531977
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210206
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 12
IP  - 5
DP  - 2021
TI  - Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in 
      advanced solid cancer: A systematic review.
PG  - 1318-1333
LID - 10.7150/jca.49174 [doi]
AB  - Aim: To evaluate the efficacy and safety of immune checkpoint inhibitor (ICI) 
      two-drug combination therapy in patients with advanced malignancy. Methods: We 
      searched PubMed, PMC, EMBASE, EBSCO, Cochrane Central Register of Controlled 
      Trials (CENTRAL), American Society of Clinical Oncology (ASCO and the European 
      Society of Medical Oncology (ESMO) to identify primary research reporting the 
      survival outcomes and safety of ICI combination therapy in patients with advanced 
      malignancy. We performed a meta-analysis that evaluated the risk ratio (RR) and 
      its 95% confidence interval (CI) for objective response rates (ORR) and disease 
      control rates (DCR), hazard ratio (HR) and 95% CI for progression-free survival 
      (PFS) and overall survival time (OS), and RR and 95% CI for adverse events (AEs). 
      Results: The final 10 studies (15 cohorts) and 2410 patients were included in the 
      meta-analysis. The ICI combination therapy resulted in improved ORR (RR 1.82, 95% 
      CI 1.31-2.54, p = 0.0004), DCR (RR 1.41, 95% CI 1.29-1.55, p < 0.0001), PFS (HR 
      0.83, 95% CI 0.74-0.94, p = 0.003) and OS (HR 0.90, 95% CI 0.82-0.98, p = 0.02) 
      in patients with advanced malignant tumors. The incidence of some high grade (>/=3) 
      AEs increased, such as fatigue, nausea, diarrhea, colitis, rash, pruritus, 
      elevated transaminase and lipase. Conclusion: Our study showed that ICI 
      combination therapy can improve ORR, DCR, PFS and OS in patients with advanced 
      malignancy. Compared with ICI monotherapy, ICI combination therapy was more 
      likely to induce severe AEs.
CI  - (c) The author(s).
FAU - Ma, Xiaoting
AU  - Ma X
AD  - Cancer Center, Beijing Friendship Hospital, Capital Medical University, No. 95 
      Yong An Road, Xi Cheng District, Beijing, 100050, China.
FAU - Zhang, Yujian
AU  - Zhang Y
AD  - Cancer Center, Beijing Friendship Hospital, Capital Medical University, No. 95 
      Yong An Road, Xi Cheng District, Beijing, 100050, China.
FAU - Wang, Shan
AU  - Wang S
AD  - Cancer Center, Beijing Friendship Hospital, Capital Medical University, No. 95 
      Yong An Road, Xi Cheng District, Beijing, 100050, China.
FAU - Wei, Huamin
AU  - Wei H
AD  - Department of Traditional Chinese Medicine, Beijing Friendship Hospital, Capital 
      Medical University, No. 95 Yong An Road, Xi Cheng District, Beijing, 100050, 
      China.
FAU - Yu, Jing
AU  - Yu J
AD  - Cancer Center, Beijing Friendship Hospital, Capital Medical University, No. 95 
      Yong An Road, Xi Cheng District, Beijing, 100050, China.
LA  - eng
PT  - Journal Article
DEP - 20210101
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC7847663
OTO - NOTNLM
OT  - ICI
OT  - combination
OT  - efficacy
OT  - malignancy
OT  - meta-analysis
OT  - safety
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2021/02/04 06:00
MHDA- 2021/02/04 06:01
PMCR- 2021/01/01
CRDT- 2021/02/03 05:58
PHST- 2020/06/07 00:00 [received]
PHST- 2020/12/06 00:00 [accepted]
PHST- 2021/02/03 05:58 [entrez]
PHST- 2021/02/04 06:00 [pubmed]
PHST- 2021/02/04 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - jcav12p1318 [pii]
AID - 10.7150/jca.49174 [doi]
PST - epublish
SO  - J Cancer. 2021 Jan 1;12(5):1318-1333. doi: 10.7150/jca.49174. eCollection 2021.